CLINICAL TRIALS AND OBSERVATIONS Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia

1Division of Hematology and Oncology, Sainte-Justine Hospital, University of Montreal, Montreal, QC, Canada; 2Departments of Pediatric Oncology, Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA; 3Division of Pediatric Hematology/Oncology, University of Rochester Medical Center, Rochester, NY; 4Division of Pediatric Hematology/Oncology, McMaster University, Hamilton, ON, Canada; 5Division of Pediatric Oncology, San Jorge Children’s Hospital, San Juan, Puerto Rico; 6Department of Pediatric Hematology/Oncology, Maine Children’s Cancer Program, Scarborough, ME; 7Centre Hospitalier Universitaire de Quebec, Quebec City, QC, Canada; 8Section of Pediatric Hematology Oncology, Tulane Hospital for Children, New Orleans, LA; 9Department of Pediatrics, Leonard M. Miller School of Medicine, University of Miami, Holtz Children’s Hospital of the University of Miami-Jackson Memorial Medical Center; Batchelor Children’s Research Institute, Mailman Institute for Child Development, and the Sylvester Comprehensive Cancer Center, Miami, FL; 10Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA; 11Division of Hematology/Oncology, Children’s Hospital, Boston, MA